Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Cell Biochem. 2019 Feb 25;120(8):12450–12460. doi: 10.1002/jcb.28512

Figure 4. M-CSF promotes human bone marrow cells CD14+CD16+ development and OC differentiation.

Figure 4.

A) Representative FACS diagrams show that the number of CD33+ cells is low in human 2adBMC. M-CSF pretreatment increased the percentage of CD14+ cells in 2adBMC. B) FACS analyses of monocyte subsets based on CD14 and CD16 expression show M-CSF pretreatment of human 2adBMC markedly increased the percentage of CD14+CD16+ intermediate monocyte, but decreased the percentage of CD14−CD16+ non-classical monocytes. C) Representative TRAP stained images show M-CSF pretreatment increased OC differentiation of human 2adBMC. D) Representative TRAP stained images show that the effect of M-CSF pretreatment on human bone marrow cells OC differentiation is not cell density-independent. E) Representative images show that CD14+ but not CD14− 2adBMC efficiently form TRAP+ OCs, and M-CSF pretreatment increased CD14+ cell OC differentiation. F) Quantification of multinuclear TRAP+ cells from F. Note: ***: p<0.001.